Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 7
2022 10
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Targeting brain metastases in breast cancer.
Corti C, Antonarelli G, Criscitiello C, Lin NU, Carey LA, Cortés J, Poortmans P, Curigliano G. Corti C, et al. Among authors: antonarelli g. Cancer Treat Rev. 2022 Feb;103:102324. doi: 10.1016/j.ctrv.2021.102324. Epub 2021 Dec 16. Cancer Treat Rev. 2022. PMID: 34953200 Review.
Harmonizing PD-L1 testing in metastatic triple negative breast cancer.
Giugliano F, Antonarelli G, Tarantino P, Cortes J, Rugo HS, Curigliano G. Giugliano F, et al. Among authors: antonarelli g. Expert Opin Biol Ther. 2022 Mar;22(3):345-348. doi: 10.1080/14712598.2022.2021180. Epub 2021 Dec 29. Expert Opin Biol Ther. 2022. PMID: 34930070 No abstract available.
Emerging treatment landscape of non-muscle invasive bladder cancer.
Valenza C, Antonarelli G, Giugliano F, Aurilio G, Verri E, Briganti A, Curigliano G, Necchi A. Valenza C, et al. Among authors: antonarelli g. Expert Opin Biol Ther. 2022 Jun;22(6):717-734. doi: 10.1080/14712598.2022.2082869. Epub 2022 May 31. Expert Opin Biol Ther. 2022. PMID: 35634893 Review.
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility.
Antonarelli G, Taurelli Salimbeni B, Marra A, Esposito A, Locatelli MA, Trapani D, Pescia C, Fusco N, Curigliano G, Criscitiello C. Antonarelli G, et al. Crit Rev Oncol Hematol. 2023 Dec;192:104148. doi: 10.1016/j.critrevonc.2023.104148. Epub 2023 Oct 1. Crit Rev Oncol Hematol. 2023. PMID: 37783318 Review.
22 results